CAPRICOR THERAPEUTICS INC (CAPR)
US14070B3096 - Common Stock
Overall CAPR gets a fundamental rating of 2 out of 10. We evaluated CAPR against 564 industry peers in the Biotechnology industry. CAPR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CAPR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CAPR had negative earnings in the past year.
CAPR had a negative operating cash flow in the past year.
In the past 5 years CAPR always reported negative net income.
In the past 5 years CAPR reported 4 times negative operating cash flow.
1.2 Ratios
CAPR's Return On Assets of -73.01% is on the low side compared to the rest of the industry. CAPR is outperformed by 69.34% of its industry peers.
Looking at the Return On Equity, with a value of -242.96%, CAPR is doing worse than 72.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.01% | ||
| ROE | -242.96% | ||
| ROIC | N/A |
ROA(3y)-48.11%
ROA(5y)-50.51%
ROE(3y)-136.19%
ROE(5y)-113.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAPR has been increased compared to 1 year ago.
CAPR has more shares outstanding than it did 5 years ago.
CAPR has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.98 indicates that CAPR is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.98, CAPR is doing good in the industry, outperforming 79.68% of the companies in the same industry.
A Debt/Equity ratio of 0.29 indicates that CAPR is not too dependend on debt financing.
CAPR's Debt to Equity ratio of 0.29 is on the low side compared to the rest of the industry. CAPR is outperformed by 69.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.98 |
ROIC/WACCN/A
WACC10.79%
2.3 Liquidity
A Current Ratio of 1.37 indicates that CAPR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.37, CAPR is doing worse than 82.71% of the companies in the same industry.
A Quick Ratio of 1.37 indicates that CAPR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.37, CAPR is doing worse than 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
CAPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.51%, which is quite impressive.
Looking at the last year, CAPR shows a very strong growth in Revenue. The Revenue has grown by 187.07%.
The Revenue has been growing by 72.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.69%
Revenue 1Y (TTM)187.07%
Revenue growth 3Y333.07%
Revenue growth 5Y72.05%
Sales Q2Q%1.39%
3.2 Future
Based on estimates for the next years, CAPR will show a small growth in Earnings Per Share. The EPS will grow by 0.76% on average per year.
The Revenue is expected to grow by 52.38% on average over the next years. This is a very strong growth
EPS Next Y-61.09%
EPS Next 2Y2.55%
EPS Next 3Y39.87%
EPS Next 5Y0.76%
Revenue Next Year-23.25%
Revenue Next 2Y34.45%
Revenue Next 3Y71.96%
Revenue Next 5Y52.38%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CAPR. In the last year negative earnings were reported.
Also next year CAPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CAPR's earnings are expected to grow with 39.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.55%
EPS Next 3Y39.87%
5. Dividend
5.1 Amount
CAPR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CAPRICOR THERAPEUTICS INC
NASDAQ:CAPR (11/4/2024, 8:00:02 PM)
After market: 18.5 -0.09 (-0.51%)18.595
-0.86 (-4.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap605.08M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.01% | ||
| ROE | -242.96% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)20.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-61.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)187.07%
Revenue growth 3Y333.07%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y